 |
Cheson: The case against maintenance Rituxan
for follicular lymphoma http://bit.ly/2XZODb
|
|
NEW Rituximab
Maintenance for the Treatment of Patients With Follicular Lymphoma:
Systematic Review and Meta-analysis of Randomized Trials medscape.com
(free login req.)
|
|
Areas of Confusion in Oncology
What Is the Role of Maintenance Rituximab in Follicular NHL? cancernetwork.com/
David G. Maloney, Reviewed
by John D. Hainsworth and Bertrand Coiffier
Should rituximab maintenance become standard therapy for
follicular lymphoma?
|
| Follicular lymphoma:
chemotherapy and/or antibodies?
Michele Ghielmini ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
- http://www.bloodjournal.org/cgi/content/full/108/10/3235
|
|
First line Rituxan
for CLL:
Single-agent rituximab as first-line and
maintenance treatment for patients with chronic lymphocytic
leukemia or small lymphocytic lymphoma: a phase II trial of the
Minnie Pearl Cancer Research Network. J Clin Oncol. 2003 May
1;21(9):1746-51. PMID:
12721250
|
| Rituximab as first-line and maintenance therapy for
patients with indolent non-hodgkin's lymphoma.
J Clin Oncol. 2002 Oct 15;20(20):4261-7. PMID:
12377971 | Related
articles
CONCLUSION: Rituximab is highly active and extremely well
tolerated as first-line single-agent therapy for indolent NHL.
First-line treatment with scheduled maintenance at 6-month
intervals produces high overall and complete response rates and a
longer progression-free survival (34 months) than has been
reported with a standard 4-week treatment.
|
|
Rituxan following R-FCM
in Relapsed follicular NHL:
Maintenance therapy with rituximab
leads to a significant prolongation of response duration after
salvage therapy with a combination of rituximab, fludarabine,
cyclophosphamide and mitoxantrone (R-FCM) in patients with
relapsed and refractory follicular and mantle cell lymphomas -
results of a prospective randomized study of the German low grade
lymphoma study group (GLSG). Blood. 2006 Aug 31; PMID:
16946304
Response duration was significantly prolonged by R-maintenance
after R-FCM with the median not being reached versus 16 months
(p=0.001). This beneficial effect was also observed when analyzing
FL (p=0.035) and MCL (p=0.049) separately.
|
|
|
|
Rituximab maintenance improves clinical outcome
of relapsed/resistant follicular non-Hodgkin's lymphoma, both in
patients with and without rituximab during induction: results of a
prospective randomized phase III intergroup trial. Blood.
2006 Jul 27; PMID:
16873669
|
|
CONSOLIDATION OF CHEMO: Rituximab (anti-CD20 monoclonal
antibody) as consolidation of first-line CHOP chemotherapy in
patients with follicular lymphoma: a phase II study. Eur J
Haematol. 2002 Jul;69(1):21-6. PMID: 12270058 - PubMed
|
|
Extended use of Rituxan in Newly diagnosed and relapsed
follicular NHL
Prolonged treatment with rituximab in patients with follicular
lymphoma significantly increases event-free survival and response
duration compared with the standard weekly x 4 schedule. Blood
2004;. PubMed
Source: http://www.ncbi.nlm.nih.gov
|
| Rituxan
maintenance for DLBCL following CHOP-R? ASCO
2007 http://bit.ly/1SkdJX
As 6-yr FFS declined to <50% among R-CHOP responders, with or
without MR, there is a need for more effective treatment
strategies in older DLBCL pts.
|
| Rituximab long-term maintenance therapy after autologous
stem cell transplantation in patients with B-cell
non-Hodgkin’s lymphoma springerlink.com
|
|
ASH 2002: Proleukin® Plus Rituxan® may Reduce
Recurrences Following Stem Cell Transplant in Non-Hodgkin’s
Lymphoma - CancerConsultants.com
|
TOPIC
SEARCH: